Crossmark

Translating evidence into practice: eligibility criteria fail to eliminate clinically significant differences between real-world and study populations

Crossref DOI link: https://doi.org/10.1038/s41746-020-0277-8

Published Online: 2020-05-11

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Averitt, Amelia J. https://orcid.org/0000-0003-1221-1123
Weng, Chunhua https://orcid.org/0000-0002-9624-0214
Ryan, Patrick

Perotte, Adler
Funding

Funding for this research was provided by:

U.S. Department of Health & Human Services | NIH | U.S. National Library of Medicine (R01LM009886-10)

U.S. Department of Health & Human Services | NIH | U.S. National Library of Medicine (T15LM007079)

U.S. Department of Health & Human Services | NIH | U.S. National Library of Medicine

Janssen Pharmaceuticals (CU15-2317)
License Information

Text and Data Mining valid from 2020-05-11

Version of Record valid from 2020-05-11
More Information

Article History

Received: 10 December 2019

Accepted: 9 April 2020

First Online: 11 May 2020

Competing interests

: P.R. is an employee of Janssen Research and Development and a shareholder of Johnson & Johnson. All other authors have no relevant conflicts of interest.

Document is current

Any future updates will be listed below